Traumatic Brain InjurySmART-TBINCT04603443
SmART-TBI: Supplementation With Amino Acid Rehabilitative Therapy in TBI
A study testing Branched Chain Amino Acids in people with Traumatic Brain Injury, run by VA Office of Research and Development at 1 site in United States.
Trial summary
The most persistent and disabling postconcussive symptoms following mild traumatic brain injury (mTBI) are sleep disturbances and cognitive dysfunction, with few tractable interventions currently available. Read more about this study
- Who is it for?
- Ages 18 to 65 years
- Conditions the study is for
- Traumatic Brain Injury
- What is being tested?
- Branched Chain Amino Acids
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 175 participants
- Where
- 1 siteUnited States
- Study dates
- 1 Jun 2021to 30 Sep 2025
- Phase
- Interventional
- Are there results?
- Yes, posted in the registrySummary in the doctors' view
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 to 65 years
- All sexes
- No healthy volunteers
- Adult, Older adult
Who may be able to join
- Be Veterans (male and female; any race; 18-65 years of age)
- Be English speaking
- Be accessible via phone
- Be non-decisionally impaired
- Attest to there being no chance of being or becoming pregnant during the study (if female)
- Attest to no history of maple syrup urine disease or known family history of maple urine syrup disease
Show all 14Show fewer
- Have either a history of self-reported sleep disturbances, either as determined via the Insomnia Severity Index, Functional Outcomes of Sleep Questionnaire or Epworth Sleepiness Scale, clinical assessment, and/or a history of self-reported cognitive disturbance (e.g., poor memory, concentration, attention)
- Not have an allergy to sucralose
- Not be a shift worker (e.g. have worked night or rotating shifts more than twice in the past month)
- Not have a diagnosis of amyotrophic lateral sclerosis
- Not be currently supplementing their diet with branched chain amino acids
- Not be starting another sleep intervention (e.g., positive airway pressure therapy for sleep apnea, sedative-hypnotic medication, or cognitive behavioral therapy for insomnia) during the study
- if already engaged in another sleep intervention, this must be stable and not undergo further changes during the study
- Meet diagnostic criteria for TBI using a validated clinical interview
Who cannot join
- Pregnancy or female trying to conceive
- Under 18 years old
- Known history of maple syrup urine disease
- Dementia
Trial locations and contacts
1 site in 1 country.
United States1 site
VA Portland Health Care System, Portland, OR
Portland, Oregon, 97207-2964
About this study
Official title: Supplementation With Amino Acid Rehabilitative Therapy in TBI (SmART-TBI): A Randomized Placebo-Controlled Trial to Improve Sleep
The most persistent and disabling postconcussive symptoms following mild traumatic brain injury (mTBI) are sleep disturbances and cognitive dysfunction, with few tractable interventions currently available. Here, a novel therapy will be tested consisting of dietary supplementation with branched chain amino acids (BCAA), based on the study team's previous preclinical work showing restoration of glutamate neurotransmitter balance in sleep and memory circuits. Supplementation with Amino acid Rehabilitative Therapy in TBI (SmART-TBI) is a randomized, placebo-controlled, double-blinded, exploratory clinical trial of BCAA intended to establish the feasibility, acceptability, and limited efficacy of long-term BCAA to improve sleep and cognition in Veterans with mTBI. These results will inform the optimal study design of a future, full-scale randomized controlled trial, including the identification of the proper dose and duration of BCAA to improve sleep and the potential subpopulations of Veterans with mTBI that may benefit the most.
Read the detailed description
Mild traumatic brain injury (mTBI) has impacted over 60% of all OEF/OIF Veterans over the past decade, and over 20% of these Veterans carry a diagnosis of postconcussion syndrome. Arguably the most disabling postconcussion symptoms are sleep-wake and cognitive disturbances. Sleep, cognitive function, and related symptoms often remain impaired >10-15 years following mTBI. Not only are these symptoms themselves exceedingly difficult to live with, but poor sleep and cognition also interfere with ongoing rehabilitation interventions, and prevent reintegration into civilian life and return to gainful employment. Most existing therapies for sleep-wake and cognitive dysfunction following mTBI are merely symptomatic, and they also suffer from low efficacy and/or patient acceptability. Thus, there is an urgent need to identify mechanism-based interventions for sleep and cognitive problems following mTBI, in order to facilitate optimal rehabilitation and functional outcomes.
The study team's long-term goal is to implement a brain-bioactive pharmacological intervention to address sleep and cognitive disturbance in individuals with mTBI. The overall objective of this application, which represents the first step towards this goal, is to test the feasibility and limited efficacy of a highly promising therapy consisting of a dietary supplement, branched chain amino acids (BCAA; i.e., leucine, isoleucine, and valine), to treat sleep disturbances in individuals with mTBI. There is compelling scientific precedent and safety data to support the testing of BCAA therapy in Veterans with mTBI. Preliminary preclinical data has shown that the mechanism of action for BCAA, acting as a precursor to the excitatory neurotransmitter glutamate, restores the balance of excitation to inhibition within the dysfunctional brain circuits for both sleep and cognition in mTBI. With these data, the study team has also meticulously mapped the optimal dosing, duration, and route of administration in mice. Further, the study team now has pilot data from a double-blinded, placebo-controlled study showing that 3 weeks of dietary BCAA supplementation, but not placebo, significantly improved self-reported sleep in Veterans. Other research groups have used dietary BCAA supplementation in humans across multiple conditions at doses up to 60 grams/day and durations up to 12 months with few to no side effects.
The central hypothesis is that BCAA dietary supplementation will improve sleep quality in Veterans with mTBI. As a first step towards testing this hypothesis, herein is proposed a long-term feasibility, acceptability, and limited efficacy study of BCAA's effects on sleep that will be randomized, placebo-controlled, and double-blinded. Veterans with mTBI will be randomly assigned to receive BCAA at 20, 40 or 60 grams/day per oral (PO) or a placebo (n=50 per group) for 12 weeks. Feasibility, acceptability, and limited efficacy outcomes based on sleep (e.g., self-report, continuous actigraphy, and overnight polysomnography) will be assessed.
Results will inform the optimal study methodology and design for a future, full-scale randomized controlled trial, including the identification of the proper dose and duration of BCAA to improve sleep and the potential subpopulations of Veterans with mTBI that may be differentially affected by BCAA. This work will aos be used to generate hypotheses on the effect of BCAA on cognition and overall quality of life measures to inform future research.
- Conditions
- Traumatic Brain Injury
- Being tested
- Branched Chain Amino Acids, Protein Control
- Keywords
- TBI, sleep, cognition, bcaa
- Medical subject headings
- Brain Injuries, Traumatic
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Branched Chain Amino AcidsDietary supplement
Also called BCAA-20
Isoleucine, Leucine, and Valine, 10g BID x 12 weeks
Branched Chain Amino AcidsDietary supplement
Also called BCAA-40
Isoleucine, Leucine, and Valine, 20g BID x 12 weeks
Branched Chain Amino AcidsDietary supplement
Also called BCAA-60
Isoleucine, Leucine, and Valine, 30g BID x 12 weeks
Protein ControlDietary supplement
Protein placebo control - all amino acids except for BCAA, 10g BID x 12 weeks
| Study group | Role | What they receive |
|---|---|---|
| BCAA 20g/daily | Experimental | Branched Chain Amino Acids, 10g BID x 12 weeks Receives: Dietary Supplement: Branched Chain Amino Acids |
| BCAA 40g/daily | Experimental | Branched Chain Amino Acids, 20g BID x 12 weeks Receives: Dietary Supplement: Branched Chain Amino Acids |
| BCAA 60g/daily | Experimental | Branched Chain Amino Acids, 30g BID x 12 weeks Receives: Dietary Supplement: Branched Chain Amino Acids |
| Placebo 20g/daily | Placebo comparator | Protein without BCAA, 10g BID x 12 weeks Receives: Dietary Supplement: Protein Control |
What is being measured
The primary outcome is the main question the study is designed to answer.
Patient Satisfaction With Overall Study Process
Likert scale (1-5, higher= more satisfied) assessing satisfaction with consent process, staff, medication dispensing and regimen, devices/equipment, sleep study, questionnaires, cognitive testing, and overall experience of the study.
Measured: 12 weeks
Monitoring of Side Effects Scale (MOSES)
Monitoring of side effects scale with emphasis on GI, neurological, psychiatric side effects. Range= 0-124, higher= more side effects.
Measured: 4 weeks
Change in Monitoring of Side Effects Scale (MOSES)
Change in average score between week 8 and week 4 for the MOSES. The monitoring of side effects scale assesses GI, neurological, psychiatric side effects. Range= 0-124, higher= more side effects.
Measured: 8 weeks
Change in Monitoring of Side Effects Scale (MOSES)
Change in average score between week 12 and week 4 for the MOSES. The monitoring of side effects scale assesses GI, neurological, psychiatric side effects. Range= 0-124, higher= more side effects.
Measured: 12 weeks
Reasons for Non-adherence
Participants could select any of the following choices (multiple options allowed) to explain what prevented them from consuming the product twice a day: Side effects, Bad taste, Inconvenience, Trouble Remembering, No Time, Did not make me feel better, or Other.
Measured: 4 weeks
Reasons for Non-adherence
Participants could select any of the following choices (multiple options allowed) to explain what prevented them from consuming the product twice a day: Side effects, Bad taste, Inconvenience, Trouble Remembering, No Time, Did not make me feel better, or Other.
Measured: 8 weeks
Reasons for Non-adherence
Participants could select any of the following choices (multiple options allowed) to explain what prevented them from consuming the product twice a day: Side effects, Bad taste, Inconvenience, Trouble Remembering, No Time, Did not make me feel better, or Other.
Measured: 12 weeks
Recruitment Source
Proportion of subjects recruited from various sources (clinical referral, flyers, ads, etc)
Measured: Year 1
Recruitment Source
Proportion of subjects recruited from various sources (clinical referral, flyers, ads, etc)
Measured: Year 2
Recruitment Source
Proportion of subjects recruited from various sources (clinical referral, flyers, ads, etc)
Measured: Year 3
Recruitment Source
Proportion of subjects recruited from various sources (clinical referral, flyers, ads, etc)
Measured: Year 4
Recruitment
Number of subjects randomized of those eligible as descriptive percent
Measured: Year 1
Recruitment
Number of subjects randomized of those eligible as descriptive percent
Measured: Year 2
Recruitment
Number of subjects randomized of those eligible as descriptive percent
Measured: Year 3
Recruitment
Number of subjects randomized of those eligible as descriptive percent
Measured: Year 4
Study Drug Adherence by Serum
Proportion of study drug consumed assessed by serum of BCAA.
Measured: 12 weeks
Study Drug Adherence by Sleep Diary
Proportion of study drug consumed assessed by sleep diary.
Measured: 12 weeks
Study Drug Adherence by Drug Accounting
Proportion of study drug consumed within each timepoint assessed by drug accounting.
Measured: 12 weeks
Actiwatch Adherence
Proportion of days with actiwatch worn
Measured: 12 weeks
Screen Failures
Number of enrolled participants who were later found ineligible
Measured: From enrollment to randomization (~4 weeks)
Incidence of Non-Participation
Reason for not participating after initial contact and before consent as descriptive percent
Measured: From first contact to declining (~1 week)
Retention by Arm
Number of participants retained by study arm
Measured: From randomization to study completion (~12 weeks)
Secondary outcomes (1)
Change in Insomnia Severity Index (ISI) From Baseline
Change in Insomnia Severity Index (ISI) range: 0-28, higher means worse sleep
Measured: 12 weeks
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted26 Oct 2020
- Study start1 Jun 2021
- Primary completion30 Sep 2025
- Study completion30 Sep 2025
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Posted resultsParticipant flow, outcome measures and adverse events reported by the sponsor.
- Other trials for Traumatic Brain InjuryStudies of the same condition, open and under way.
- More trials run by VA Office of Research and DevelopmentThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Model description
- Randomized, double-blinded, placebo-controlled feasibility study
- Masking
- Triple blind
- Who is masked
- Participant, Investigator, Outcomes assessor
- Enrolment
- 175 participants (actual)
Sponsor and investigators
- Lead sponsor
- VA Office of Research and Development
- Sponsor type
- US federal agency
- Responsible party
- Sponsor
- Investigators
- Miranda M Lim, MD PhD, Principal investigator, VA Portland Health Care System, Portland, OR
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT04603443
- Sponsor's protocol ID
- NURR-003-19F
- Other IDs
- I01CX002022
- Acronym
- SmART-TBI
- Status last verified
- Oct 2026
- First submitted
- 2 Oct 2020
- Last updated
- 28 Oct 2026
- Results posted
- Yes, on ClinicalTrials.gov
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Yes: A limited dataset (LDS) will be created and shared pursuant to a Data Use Agreement (DUA) appropriately limiting use of the dataset and prohibiting the recipient from identifying or re-identifying any individual whose data are included in the dataset.
Study at a glance
From the registry record, last updated by the sponsor on 28 Oct 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Supplementation With Amino Acid Rehabilitative Therapy in TBI (SmART-TBI): A Randomized Placebo-Controlled Trial to Improve Sleep
- ClinicalTrials.gov ID
- NCT04603443
- Acronym / sponsor ID
- SmART-TBI / NURR-003-19F
- Conditions
- Traumatic Brain Injury
- Keywords
- TBI, sleep, cognition, bcaa
- Study type
- Interventional
- Recruitment status
- Completed
- Enrolment
- 175 participants (actual)
- Lead sponsor
- VA Office of Research and DevelopmentUS federal agency
- Collaborators
- Children's Hospital of Philadelphia, Oregon Health and Science University
- Study start
- 1 Jun 2021 (actual)
- Primary completion
- 30 Sep 2025 (actual)
- Study completion
- 30 Sep 2025 (actual)
- First posted
- 26 Oct 2020 (actual)
- Results
- Posted 1 Oct 2026
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The most persistent and disabling postconcussive symptoms following mild traumatic brain injury (mTBI) are sleep disturbances and cognitive dysfunction, with few tractable interventions currently available. Here, a novel therapy will be tested consisting of dietary supplementation with branched chain amino acids (BCAA), based on the study team's previous preclinical work showing restoration of glutamate neurotransmitter balance in sleep and memory circuits. Supplementation with Amino acid Rehabilitative Therapy in TBI (SmART-TBI) is a randomized, placebo-controlled, double-blinded, exploratory clinical trial of BCAA intended to establish the feasibility, acceptability, and limited efficacy of long-term BCAA to improve sleep and cognition in Veterans with mTBI. These results will inform the optimal study design of a future, full-scale randomized controlled trial, including the identification of the proper dose and duration of BCAA to improve sleep and the potential subpopulations of Veterans with mTBI that may benefit the most.
Detailed description
Mild traumatic brain injury (mTBI) has impacted over 60% of all OEF/OIF Veterans over the past decade, and over 20% of these Veterans carry a diagnosis of postconcussion syndrome. Arguably the most disabling postconcussion symptoms are sleep-wake and cognitive disturbances. Sleep, cognitive function, and related symptoms often remain impaired >10-15 years following mTBI. Not only are these symptoms themselves exceedingly difficult to live with, but poor sleep and cognition also interfere with ongoing rehabilitation interventions, and prevent reintegration into civilian life and return to gainful employment. Most existing therapies for sleep-wake and cognitive dysfunction following mTBI are merely symptomatic, and they also suffer from low efficacy and/or patient acceptability. Thus, there is an urgent need to identify mechanism-based interventions for sleep and cognitive problems following mTBI, in order to facilitate optimal rehabilitation and functional outcomes.
The study team's long-term goal is to implement a brain-bioactive pharmacological intervention to address sleep and cognitive disturbance in individuals with mTBI. The overall objective of this application, which represents the first step towards this goal, is to test the feasibility and limited efficacy of a highly promising therapy consisting of a dietary supplement, branched chain amino acids (BCAA; i.e., leucine, isoleucine, and valine), to treat sleep disturbances in individuals with mTBI. There is compelling scientific precedent and safety data to support the testing of BCAA therapy in Veterans with mTBI. Preliminary preclinical data has shown that the mechanism of action for BCAA, acting as a precursor to the excitatory neurotransmitter glutamate, restores the balance of excitation to inhibition within the dysfunctional brain circuits for both sleep and cognition in mTBI. With these data, the study team has also meticulously mapped the optimal dosing, duration, and route of administration in mice. Further, the study team now has pilot data from a double-blinded, placebo-controlled study showing that 3 weeks of dietary BCAA supplementation, but not placebo, significantly improved self-reported sleep in Veterans. Other research groups have used dietary BCAA supplementation in humans across multiple conditions at doses up to 60 grams/day and durations up to 12 months with few to no side effects.
The central hypothesis is that BCAA dietary supplementation will improve sleep quality in Veterans with mTBI. As a first step towards testing this hypothesis, herein is proposed a long-term feasibility, acceptability, and limited efficacy study of BCAA's effects on sleep that will be randomized, placebo-controlled, and double-blinded. Veterans with mTBI will be randomly assigned to receive BCAA at 20, 40 or 60 grams/day per oral (PO) or a placebo (n=50 per group) for 12 weeks. Feasibility, acceptability, and limited efficacy outcomes based on sleep (e.g., self-report, continuous actigraphy, and overnight polysomnography) will be assessed.
Results will inform the optimal study methodology and design for a future, full-scale randomized controlled trial, including the identification of the proper dose and duration of BCAA to improve sleep and the potential subpopulations of Veterans with mTBI that may be differentially affected by BCAA. This work will aos be used to generate hypotheses on the effect of BCAA on cognition and overall quality of life measures to inform future research.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Triple blind (participant, investigator, outcomes assessor)
- Number of arms
- 4
- Model description
- Randomized, double-blinded, placebo-controlled feasibility study
| Arm | Type | Receives |
|---|---|---|
| BCAA 20g/daily | Experimental | Dietary Supplement: Branched Chain Amino AcidsBranched Chain Amino Acids, 10g BID x 12 weeks |
| BCAA 40g/daily | Experimental | Dietary Supplement: Branched Chain Amino AcidsBranched Chain Amino Acids, 20g BID x 12 weeks |
| BCAA 60g/daily | Experimental | Dietary Supplement: Branched Chain Amino AcidsBranched Chain Amino Acids, 30g BID x 12 weeks |
| Placebo 20g/daily | Placebo comparator | Dietary Supplement: Protein ControlProtein without BCAA, 10g BID x 12 weeks |
Who may qualify
- Ages
- 18 to 65 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
Key inclusion criteria (14 listed)
- Be Veterans (male and female; any race; 18-65 years of age)
- Be English speaking
- Be accessible via phone
- Be non-decisionally impaired
- Attest to there being no chance of being or becoming pregnant during the study (if female)
Key exclusion criteria (4 listed)
- Pregnancy or female trying to conceive
- Under 18 years old
- Known history of maple syrup urine disease
- Dementia
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Branched Chain Amino AcidsAlso: BCAA-20Isoleucine, Leucine, and Valine, 10g BID x 12 weeks | Dietary supplement | BCAA 20g/daily |
| Branched Chain Amino AcidsAlso: BCAA-40Isoleucine, Leucine, and Valine, 20g BID x 12 weeks | Dietary supplement | BCAA 40g/daily |
| Branched Chain Amino AcidsAlso: BCAA-60Isoleucine, Leucine, and Valine, 30g BID x 12 weeks | Dietary supplement | BCAA 60g/daily |
| Protein ControlProtein placebo control - all amino acids except for BCAA, 10g BID x 12 weeks | Dietary supplement | Placebo 20g/daily |
Primary outcome
Patient Satisfaction With Overall Study Process
Time frame: 12 weeks
Likert scale (1-5, higher= more satisfied) assessing satisfaction with consent process, staff, medication dispensing and regimen, devices/equipment, sleep study, questionnaires, cognitive testing, and overall experience of the study.
Monitoring of Side Effects Scale (MOSES)
Time frame: 4 weeks
Monitoring of side effects scale with emphasis on GI, neurological, psychiatric side effects. Range= 0-124, higher= more side effects.
Change in Monitoring of Side Effects Scale (MOSES)
Time frame: 8 weeks
Change in average score between week 8 and week 4 for the MOSES. The monitoring of side effects scale assesses GI, neurological, psychiatric side effects. Range= 0-124, higher= more side effects.
Change in Monitoring of Side Effects Scale (MOSES)
Time frame: 12 weeks
Change in average score between week 12 and week 4 for the MOSES. The monitoring of side effects scale assesses GI, neurological, psychiatric side effects. Range= 0-124, higher= more side effects.
Reasons for Non-adherence
Time frame: 4 weeks
Participants could select any of the following choices (multiple options allowed) to explain what prevented them from consuming the product twice a day: Side effects, Bad taste, Inconvenience, Trouble Remembering, No Time, Did not make me feel better, or Other.
Reasons for Non-adherence
Time frame: 8 weeks
Participants could select any of the following choices (multiple options allowed) to explain what prevented them from consuming the product twice a day: Side effects, Bad taste, Inconvenience, Trouble Remembering, No Time, Did not make me feel better, or Other.
Reasons for Non-adherence
Time frame: 12 weeks
Participants could select any of the following choices (multiple options allowed) to explain what prevented them from consuming the product twice a day: Side effects, Bad taste, Inconvenience, Trouble Remembering, No Time, Did not make me feel better, or Other.
Recruitment Source
Time frame: Year 1
Proportion of subjects recruited from various sources (clinical referral, flyers, ads, etc)
Recruitment Source
Time frame: Year 2
Proportion of subjects recruited from various sources (clinical referral, flyers, ads, etc)
Recruitment Source
Time frame: Year 3
Proportion of subjects recruited from various sources (clinical referral, flyers, ads, etc)
Recruitment Source
Time frame: Year 4
Proportion of subjects recruited from various sources (clinical referral, flyers, ads, etc)
Recruitment
Time frame: Year 1
Number of subjects randomized of those eligible as descriptive percent
Recruitment
Time frame: Year 2
Number of subjects randomized of those eligible as descriptive percent
Recruitment
Time frame: Year 3
Number of subjects randomized of those eligible as descriptive percent
Recruitment
Time frame: Year 4
Number of subjects randomized of those eligible as descriptive percent
Study Drug Adherence by Serum
Time frame: 12 weeks
Proportion of study drug consumed assessed by serum of BCAA.
Study Drug Adherence by Sleep Diary
Time frame: 12 weeks
Proportion of study drug consumed assessed by sleep diary.
Study Drug Adherence by Drug Accounting
Time frame: 12 weeks
Proportion of study drug consumed within each timepoint assessed by drug accounting.
Actiwatch Adherence
Time frame: 12 weeks
Proportion of days with actiwatch worn
Screen Failures
Time frame: From enrollment to randomization (~4 weeks)
Number of enrolled participants who were later found ineligible
Incidence of Non-Participation
Time frame: From first contact to declining (~1 week)
Reason for not participating after initial contact and before consent as descriptive percent
Retention by Arm
Time frame: From randomization to study completion (~12 weeks)
Number of participants retained by study arm
1 secondary outcome
Change in Insomnia Severity Index (ISI) From Baseline
Time frame: 12 weeks
Results and safety
Loading the posted results from ClinicalTrials.gov…
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 28 Oct 2026.
- Posted resultsParticipant flow, baseline, all outcome measures and adverse events.
- Individual participant dataSharing planned: Yes. A limited dataset (LDS) will be created and shared pursuant to a Data Use Agreement (DUA) appropriately limiting use of the dataset and prohibiting the recipient from identifying or re-identifying any individual whose data are included in the dataset.
Related trials for Traumatic Brain Injury
Active, not recruitingObservational study
Transforming Research and Clinical Knowledge in Traumatic Brain Injury Epileptogenesis Project (TRACK-TBI EPI)
Traumatic Brain Injury, Post-traumatic Epilepsy
Enrolling by invitationPhase 1
Pilot Safety and Exploratory Efficacy of PSC-05 for the Treatment of Chronic Mild Traumatic Brain Injury
Mild Traumatic Brain Injury
RecruitingObservational study
Intracranial Pressure Monitoring in Moderate Traumatic Brain Injury
Moderate Traumatic Brain Injury
Not yet recruitingPhase 1
Nanopulse Laser Therapy
TBI (Traumatic Brain Injury)
RecruitingObservational study
Effect of Different Intravenous Fluids on Post-operative Chronic Subdural Hematoma Size and Recurrence
Chronic Subdural Hematoma
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Miranda M Lim, MD PhD principal investigator
VA Portland Health Care System, Portland, OR
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Branched Chain Amino Acids in people with Traumatic Brain Injury, run by VA Office of Research and Development at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 14 inclusion and 4 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: finished, as of the sponsor's last update on 28 Oct 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
Yes. Results are posted in the registry (first posted 1 Oct 2026). A summary is in the For doctors view, and the full results are on ClinicalTrials.gov.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Patient Satisfaction With Overall Study Process (time frame: 12 weeks). The study lists 22 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 28 Oct 2026.